@inproceedings{inproceedings, title  = {{Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with ErbB2+(HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective}},

 url = {{}},

 year = {{2007}},

 month = {{9}},

 author = {{Delea TE and Tappenden P and Sofrygin O and Karnon J and Amonkar M and Browning D and Rudge H and Walker M}},

 volume = {{5}},

 journal = {{EJC SUPPLEMENTS}},

 issue = {{4}},

 pages = {{225-225}},

 note = {{Accessed on 2025/04/05}}}